Ciprofloxacin
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cholera
Conditions
Cholera
Trial Timeline
May 1, 2001 → Jul 1, 2002
NCT ID
NCT00142272About Ciprofloxacin
Ciprofloxacin is a phase 3 stage product being developed by Bayer for Cholera. The current trial status is completed. This product is registered under clinical trial identifier NCT00142272. Target conditions include Cholera.
What happened to similar drugs?
2 of 7 similar drugs in Cholera were approved
Approved (2) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00669994 | Approved | Completed |
| NCT00142272 | Phase 3 | Completed |
Competing Products
9 competing products in Cholera
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Azithromycin | Pfizer | Phase 3 | 40 |
| Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell | Sanofi | Phase 3 | 40 |
| Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell | Sanofi | Approved | 43 |
| PXVX0200 + placebo | Bavarian Nordic | Phase 3 | 37 |
| PXVX0200 + Placebo | Bavarian Nordic | Phase 3 | 37 |
| VAXCHORA (Cholera Vaccine, Live, Oral) | Bavarian Nordic | Approved | 40 |
| PXVX0200 Lot A + PXVX0200 Lot B + PXVX0200 Lot C + Placebo | Bavarian Nordic | Phase 3 | 37 |
| PXVX0200 + Placebo | Bavarian Nordic | Phase 1 | 26 |
| PXVX0200 10E8 + PXVX0200 10E9 + Placebo + Shanchol | Emergent BioSolutions | Phase 2 | 25 |